Cannabinoid receptor 1–5-hydroxytryptamine receptor 2A heterodimer interface (CB1R–5-HT2A interface)

The Cannabinoid receptor 1–5-hydroxytryptamine receptor 2A (CB1R–5-HT2A) heterodimer interface is a specialized pharmacological target formed by the physical interaction of two major G protein-coupled receptors in the central nervous system. This heteromeric complex is predominantly expressed in brain regions critical for cognition and emotion, such as the cerebral cortex, hippocampus, and striatum (Viñals et al., 2015, Nature Medicine). Research has demonstrated that the formation of this specific heterodimer is responsible for the cognitive and memory-impairing effects of Δ9-tetrahydrocannabinol (THC), while the analgesic effects of cannabinoids are mediated by individual CB1 receptors (Viñals et al., 2015). By targeting the physical interface of this complex—often through the use of interfering peptides or bivalent ligands—it is possible to decouple the therapeutic benefits of cannabinoid signaling from its adverse neuropsychiatric side effects. The interface allows for unique signaling cross-talk, where 5-HT2A receptor antagonists can block CB1-mediated effects and vice versa, a phenomenon known as cross-antagonism (Galindo et al., 2018, Frontiers in Pharmacology). This target is of significant interest in the development of novel treatments for schizophrenia, anxiety, and memory disorders, as it offers a way to modulate specific neural circuits without the broad side effects associated with global receptor inhibition.

Other names

CB1-5-HT2A heteromer interfaceCB1R-5HT2AR complex interfaceCannabinoid-Serotonin receptor heteromerCB1-5HT2A heteromer

The interface facilitates bidirectional allosteric communication between CB1 and 5-HT2A receptors, where the activation of one protomer modulates the signaling, G-protein coupling, and trafficking of the partner receptor, often leading to unique downstream pathways such as Gq/11-mediated signaling that are not typical for monomeric CB1R.